Presenter: Grzegorz Halena, MD, PhD

Affiliation: Medical University of Gdańsk, Poland

Abstract

Multicenter data (6 centers, n=146) confirms: Fluency™ Plus stent graft achieves 6.9% 12-month TLR and 77.5% 5-year primary patency for iliac aneurysms/occlusive disease, establishing its role in complex iliac interventions.

Introduction

Iliac artery pathologies demand durable endovascular solutions. While Bard's Fluency™ Plus stent graft (max Ø13.5mm) excels in BEVAR and dialysis access, its performance in primary iliac lesions requires robust validation.

Key Findings (2010-2020 Cohort)

1.Patient Profile

156 limbs (mean age 69.2), 55.8% aneurysms, 23.1% AIOD

44.2% common iliac artery lesions, kissing stents in only 3.5%

2.Long-Term Disparity

Aneurysm superiority: 86.3% vs 62.8% patency in AIOD at 5 years

Stable AIOD outcomes: 91% sustained clinical success over 5 years

Fluency™ Plus Advantages

Structural Design

2mm bare ends minimize edge stenosis

Outperforms full-covered stents (e.g., Covera) in bifurcation flow preservation

Emergency Utility

97.9% safety endpoint in 22.4% emergency cases (including ruptures)

Complex Case Proof

Common iliac aneurysm repair with patent stent at 7-year follow-up

Conclusions

1.Fluency™ Plus is preferred for iliac aneurysms (>86% 5-yr patency); AIOD requires vigilant surveillance

2.Bare ends reduce restenosis: Uncovered segments accommodate bifurcation hemodynamics

3.Critical knowledge gap: Comparative studies needed for external iliac lesions (stent vs stent-graft)

Clinical Alert: 62.8% 5-year patency in AIOD underscores aggressive risk factor control in atherosclerotic patients.